Christine Hicking

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Neuro-oncology, Glioma, Medicine +9

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 439 citations · Full text

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial

Christopher G. Goetz, Philippe Damier, Christine Hicking et al. · Movement Disorders · 2006 · 252 citations

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Burt Nabors, Karen Fink, Tom Mikkelsen et al. · Neuro-Oncology · 2015 · 231 citations · Full text

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Stuart D. Cook, Gavin Giovannoni, Peter Rieckmann et al. · Multiple Sclerosis and Related Disorders · 2019 · 134 citations · Full text